Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn's Disease.
Crohn’s disease
Inflammatory bowel disease
Pharmacokinetics
Ustekinumab
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
25
07
2022
accepted:
01
01
2023
medline:
18
5
2023
pubmed:
16
3
2023
entrez:
15
3
2023
Statut:
ppublish
Résumé
It is unknown whether ustekinumab (UST) levels can predict clinical outcomes in Crohn's disease (CD) patients. We assessed the exposure-response relationship of UST trough concentrations with biochemical outcomes at week 24 in a prospective, real-world setting. We performed a prospective study in patients with CD starting UST in four academic centres in the Netherlands. All patients received a weight-adjusted intravenous (IV) UST induction dose, followed by one subcutaneous (SC) dose of 90 mg UST at 8 weeks. Maintenance therapy consisted of 90 mg subcutaneous UST every 8 or 12 weeks. Individual UST concentration time course during treatment were estimated using a population pharmacokinetic (PK) model. Quartile analysis and logistic regression were performed to analyse if UST concentrations at week 8 were associated with biochemical remission rates at week 24 (C-reactive protein (CRP) ≤ 5 mg/L and / or faecal calprotectin (FC) ≤ 250 mg/kg). In total, 124 patients with CD were included. Patients achieving biochemical remission at week 12 and 24 had significantly higher UST levels at week 8 compared to patients without biochemical remission (6.6 µg/mL versus 3.9 µg/mL, P < 0.01 and 6.3 µg/mL versus 3.9 µg/mL, P < 0.01, respectively). In quartile analysis, patients with UST levels in the highest quartile (≥ 6.3 µg/mL at week 8) had higher biochemical remission rates at week 12 and week 24. There was no association between UST levels at and corticosteroid-free clinical remission rates. In this real-world cohort of patients with CD, UST levels in the highest quartile (≥ 6.3 µg/mL) at week 8 were associated with higher biochemical remission rates at week 24.
Identifiants
pubmed: 36920666
doi: 10.1007/s10620-023-07822-7
pii: 10.1007/s10620-023-07822-7
pmc: PMC10188378
doi:
Substances chimiques
Ustekinumab
FU77B4U5Z0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2647-2657Informations de copyright
© 2023. The Author(s).
Références
Baumgart DC, Sandborn WJ. “Crohn’s disease,” (in eng). Lancet 2012;380:1590–1605. https://doi.org/10.1016/s0140-6736(12)60026-9 .
doi: 10.1016/s0140-6736(12)60026-9
pubmed: 22914295
Deepak P, Sandborn WJ. “Ustekinumab and Anti-Interleukin-23 Agents in Crohn’s Disease,” (in eng). Gastroenterol Clin North Am 2017;46:603–626. https://doi.org/10.1016/j.gtc.2017.05.013 .
doi: 10.1016/j.gtc.2017.05.013
pubmed: 28838418
Peluso I, Pallone F, Monteleone G. “Interleukin-12 and Th1 immune response in Crohn’s disease: pathogenetic relevance and therapeutic implication,” (in eng). World J Gastroenterol 2006;12:5606–5610. https://doi.org/10.3748/wjg.v12.i35.5606 .
doi: 10.3748/wjg.v12.i35.5606
pubmed: 17007011
pmcid: 4088159
Neurath MF. “IL-23: a master regulator in Crohn disease,” (in eng). Nat Med 2007;13:26–28. https://doi.org/10.1038/nm0107-26 .
doi: 10.1038/nm0107-26
pubmed: 17206128
Feagan BG, Sandborn WJ, Gasink C et al. “Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease,” (in eng). N Engl J Med 2016;375:1946–1960. https://doi.org/10.1056/NEJMoa1602773 .
doi: 10.1056/NEJMoa1602773
pubmed: 27959607
Sandborn WJ, Rutgeers P, Gasink C et al. “Long-term efficacy and safety of ustekinumab for Crohn’s disease through the second year of therapy,” (in eng). Alimentary Pharmacology & Therapeutics 2018;48:65–77. https://doi.org/10.1111/apt.14794 .
doi: 10.1111/apt.14794
Vande Casteele N, Herfarth H, Katz J, Falck-Ytter Y, Singh S. “American Gastroenterological Association Institute Technical Review on the Role of Therapeutic Drug Monitoring in the Management of Inflammatory Bowel Diseases,” (in eng). Gastroenterology 2017;153:835–857. https://doi.org/10.1053/j.gastro.2017.07.031 .
doi: 10.1053/j.gastro.2017.07.031
pubmed: 28774547
Papamichael K, Vogelzang EH, Lambert J, Wolbink G, Cheifetz AS. “Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases,” (in eng). Expert Rev Clin Immunol 2019;15:837–848. https://doi.org/10.1080/1744666x.2019.1630273 .
doi: 10.1080/1744666x.2019.1630273
pubmed: 31180729
Khanna R, Levesque BG, Sandborn WJ, Feagan BG. “Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease,” (in eng). Gastroenterol Hepatol (N Y) 2014;10:478–489.
pubmed: 28845139
Mitrev N, vande Casteele N, Seow CH et al. “Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases,” (in eng). Aliment Pharmacol Ther 2017;46:1037–1053. https://doi.org/10.1111/apt.14368 .
doi: 10.1111/apt.14368
pubmed: 29027257
Adedokun OJ, Xu Z, Gasink C et al. “Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn’s Disease,” (in eng). Gastroenterology 2018;154:1660–1671. https://doi.org/10.1053/j.gastro.2018.01.043 .
doi: 10.1053/j.gastro.2018.01.043
pubmed: 29409871
Battat R, Kopylov U, Bessissow T et al. “Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn’s Disease,” (in eng). Clin Gastroenterol Hepatol 2017;15:1427–1434. https://doi.org/10.1016/j.cgh.2017.03.032 .
doi: 10.1016/j.cgh.2017.03.032
pubmed: 28365485
Verstockt B, Dreesen E, Noman M et al. “Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates,” (in eng). J Crohns Colitis 2019;13:864–872. https://doi.org/10.1093/ecco-jcc/jjz008 .
doi: 10.1093/ecco-jcc/jjz008
pubmed: 30715258
Painchart C, Brabantm S, Duveau N et al. “Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn’s Disease,” (in eng). Dig Dis Sci 2020;65:1445–1452. https://doi.org/10.1007/s10620-019-05865-3 .
doi: 10.1007/s10620-019-05865-3
pubmed: 31599389
Soufflet N, Bosschetti G, Robin X et al. “Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn’s Disease,” (in eng). Clin Gastroenterol Hepatol 2019;17:2610–2612. https://doi.org/10.1016/j.cgh.2019.02.042 .
doi: 10.1016/j.cgh.2019.02.042
pubmed: 30851477
Biemans VBC, van der Meulen AE, van der Woude CJ et al. “Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study,” (in eng). J Crohns Colitis 2020;14:33–45. https://doi.org/10.1093/ecco-jcc/jjz119 .
doi: 10.1093/ecco-jcc/jjz119
pubmed: 31219157
Straatmijer T et al. “Ustekinuma b for Crohn’s Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study,” (in eng). J Crohns Colitis 2021;15:1920–1930. https://doi.org/10.1093/ecco-jcc/jjab081 .
doi: 10.1093/ecco-jcc/jjab081
pubmed: 33909062
N. Holford. “The visual predictive check - superiority to standard diagnostic (Rorschach) plots. https://www.page-meeting.org/?abstract=972 (accessed.
Jonsson EN, Karlsson MO. “Xpose–an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM,” (in eng). Comput Methods Programs Biomed 1999;58:51–64. https://doi.org/10.1016/s0169-2607(98)00067-4 .
doi: 10.1016/s0169-2607(98)00067-4
pubmed: 10195646
Lindbom L, Pihlgren P, Jonsson EN. “PsN-Toolkit–a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM,” (in eng). Comput Methods Programs Biomed 2005;79:241–257. https://doi.org/10.1016/j.cmpb.2005.04.005 .
doi: 10.1016/j.cmpb.2005.04.005
pubmed: 16023764
S. L. Beal S, Boeckmann A. NONMEM user's guides. Ellicott City: ICON Development Solutions. (accessed.
Keizer RJ, van Benten M, Beijnen JH, Schellens JH, Huitema AD. “Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM,” (in eng). Comput Methods Programs Biomed 2011;101:72–79. https://doi.org/10.1016/j.cmpb.2010.04.018 .
doi: 10.1016/j.cmpb.2010.04.018
pubmed: 20627442
R. D. C. Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing. (accessed.
FDA. Clinical Pharmacology Biopharmaceutics Review(s). https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761044Orig1s000TOC.cfm (accessed.
Peyrin-Biroulet L, Reinisch W, Colombel JF et al. “Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial,” (in eng). Gut 2014;63:88–95. https://doi.org/10.1136/gutjnl-2013-304984 .
doi: 10.1136/gutjnl-2013-304984
pubmed: 23974954
Salbato J, Parnell J, Reddy R et al. “Validation of a Homogenous Mobility Shift Assay (HSMA) for the Measurement of Golimumab (GLM) and Antibodies to Golimumab (ATG) in Inflammatory Bowel Disease (IBD) Patient Serum: 1794,". Official Journal of the American College of Gastroenterology | ACG 2013;108:S540–S541.
doi: 10.14309/00000434-201310001-01794
Gorovits B, Baltrukonis DJ, Bhattacharya I et al. “Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab,” (in eng). Clin Exp Immunol 2018;192:348–365. https://doi.org/10.1111/cei.13112 .
doi: 10.1111/cei.13112
pubmed: 29431871
pmcid: 5980437
Alsoud D, Vermeire S, Verstockt B. “Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?,” (in eng). Curr Opin Pharmacol 2020;55:17–30. https://doi.org/10.1016/j.coph.2020.09.002 .
doi: 10.1016/j.coph.2020.09.002
pubmed: 33039940
Wils P, Bouhnik Y, Michetti P et al. “Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn’s Disease Refractory to Anti-Tumor Necrosis Factor Agents,” (in eng). Clin Gastroenterol Hepatol 2016;14:242-50.e1–2. https://doi.org/10.1016/j.cgh.2015.09.018 .
doi: 10.1016/j.cgh.2015.09.018
pubmed: 26432476
Kopylov U, Afif W, Cohen A et al. “Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease–the McGill experience,” (in eng). J Crohns Colitis 2014;8:1516–1522. https://doi.org/10.1016/j.crohns.2014.06.005 .
doi: 10.1016/j.crohns.2014.06.005
pubmed: 24996483
Shah SC, Colombel JF, Sands BE, Narula N. “Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn’s disease,” (in eng). Aliment Pharmacol Ther 2016;43:317–333. https://doi.org/10.1111/apt.13475 .
doi: 10.1111/apt.13475
pubmed: 26607562
Jones J, Loftus EV, Panaccione R et al. “Relationships between disease activity and serum and fecal biomarkers in patients with Crohn’s disease,” (in eng). Clin Gastroenterol Hepatol 2008;6:1218–1224. https://doi.org/10.1016/j.cgh.2008.06.010 .
doi: 10.1016/j.cgh.2008.06.010
pubmed: 18799360
Menting SP, van den Reek JMPA, Baerveldt EM et al. “The correlation of clinical efficacy, serum trough levels and antidrug antibodies in ustekinumab-treated patients with psoriasis in a clinical-practice setting,” (in eng). Br J Dermatol 2015;173(3):855–857. https://doi.org/10.1111/bjd.13834 .
doi: 10.1111/bjd.13834
pubmed: 25865153
Kopylov U, Yung DE, Engel T et al. “Fecal calprotectin for the prediction of small-bowel Crohn’s disease by capsule endoscopy: a systematic review and meta-analysis,” (in eng). Eur J Gastroenterol Hepatol 2016;28:1137–1144. https://doi.org/10.1097/meg.0000000000000692 .
doi: 10.1097/meg.0000000000000692
pubmed: 27415156
Iborra M et al. “Real-world long-term effectiveness of ustekinumab in Crohn’s disease: results from the ENEIDA registry,” (in eng). Aliment Pharmacol Ther. 2020. https://doi.org/10.1111/apt.15958 .
doi: 10.1111/apt.15958
pubmed: 32770851
Khorrami S et al. “Ustekinumab for the Treatment of Refractory Crohn’s Disease: The Spanish Experience in a Large Multicentre Open-label Cohort,” (in eng). Inflamm Bowel Dis 2016;22:1662–1669. https://doi.org/10.1097/mib.0000000000000842 .
doi: 10.1097/mib.0000000000000842
pubmed: 27306072
Kubesch A et al. “Short and Long-Term Effectiveness of Ustekinumab in Patients with Crohn’s Disease: Real-World Data from a German IBD Cohort,” (in eng). J Clin Med. 2019. https://doi.org/10.3390/jcm8122140 .
doi: 10.3390/jcm8122140
pubmed: 31817134
pmcid: 6947251
Liefferinckx C et al. “Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn’s Disease Who Failed Biologic Therapies: A National Cohort Study,” (in eng). J Crohns Colitis 2019;13:1401–1409. https://doi.org/10.1093/ecco-jcc/jjz080 .
doi: 10.1093/ecco-jcc/jjz080
pubmed: 30989232